Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea
Yujin Shin, Ji Hye Moon, Ho Jun Chin, Ele Ferrannini, Soo Lim
Endocrinol Metab. 2020;35(2):329-338.   Published online 2020 Jun 24     DOI: https://doi.org/10.3803/EnM.2020.35.2.329
Citations to this article as recorded by Crossref logo
Correlation of dynamic membrane fluctuations in red blood cells with diabetes mellitus and cardiovascular risks
Minji Sohn, Ji Eun Lee, MinGeun Ahn, YongKeun Park, Soo Lim
Scientific Reports.2021;[Epub]     CrossRef
Comparison betweeen dapagliflozin add-on therapy and insulin dose escalation in patients with uncontrolled type 2 diabetes treated with insulin: DVI study
Yujin Shin, Haeri Choi, Soo Lim
Diabetes Research and Clinical Practice.2021; 175: 108843.     CrossRef
Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study
Satilmis Bilgin, Ozge Kurtkulagi, Tuba Taslamacioglu Duman, Burcin Meryem Atak Tel, Gizem Kahveci, Murat Kiran, Eray Erge, Gulali Aktas
Irish Journal of Medical Science (1971 -).2021;[Epub]     CrossRef
Impact of COVID-19 and Associated Preventive Measures on Cardiometabolic Risk Factors in South Korea
Minji Sohn, Bo Kyung Koo, Ho Il Yoon, Kyoung-Ho Song, Eu Suk Kim, Hong Bin Kim, Soo Lim
Journal of Obesity & Metabolic Syndrome.2021; 30(3): 248.     CrossRef